Are calcium antagonists beneficial in diabetic patients with hypertension?

American Journal of Medicine

Volumn 116, Issue 1, 2004, Pages 44-49

  Grossman, Ehud ^a   Messerli, Franz H ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; ISRADIPINE; LISINOPRIL; LOSARTAN; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE;

BLOOD PRESSURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDLINE; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK; STROKE; TREATMENT OUTCOME;

EID: 0346098176     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.07.015     Document Type: Review

References (37)

1. Abernethy D.R., Schwartz J.B. Calcium-antagonist drugs. N Engl J Med. 341:1999;1447-1457.
2. Tuomilehto J., Rastenyte D., Birkenhager W.H., et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 340:1999;677-684.
3. Fagan T.C., Sowers J. Type 2 diabetes mellitus greater cardiovascular risks and greater benefits of therapy . Arch Intern Med. 159:1999;1033-1034.
4. Epstein M., Sowers J.R. Diabetes mellitus and hypertension. Hypertension. 19:1992;403-418.
5. Gahlinger P.M., Abramson J.H. CASECONT in Programs for Epidemiologic Analysis (PEPI). Version 2. 1995;USA Inc, Stone Mountain, Georgia. 33-41.
6. Fleiss J.L. Statistical Methods for Rates and Proportions. 2nd ed :1991;John Wiley & Sons, New York, New York.
7. Estacio R.O., Schrier R.W. Antihypertensive therapy in type 2 diabetes implications of the Appropriate Blood Pressure Control in Diabetes (ABCD) trial . Am J Cardiol. 82:1998;9R-14R.
8. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 338:1998;645-652.
9. Tatti P., Pahor M., Byington R.P., et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 21:1998;597-603.
10. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group . Lancet. 351:1998;1755-1762.
11. Niskanen L., Hedner T., Hansson L., et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen a subanalysis of the Captopril Prevention Project . Diabetes Care. 24:2001;2091-2096.
12. Curb J.D., Pressel S.L., Cutler J.A., et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group [published correction appears in JAMA. 1997;277:1356]. JAMA. 276:1996;1886-1892.
13. Wang J.G., Staessen J.A., Liu L.S. Subgroup analysis of the placebo-controlled Chinese trial on isolated systolic hypertension in the elderly. J Hypertens. 17:(suppl 3):1999;S86.
14. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 39 . BMJ. 317:1998;713-720.
15. Hansson L., Lindholm L.H., Ekbom T., et al. Randomized trial of old and new antihypertensive drugs in elderly patients cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study . Lancet. 354:1999;1751-1756.
16. Lindholm L.H., Hansson L., Ekbom T., et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group . J Hypertens. 18:2000;1671-1675.
17. Mancia G., Brown M., Castaigne A., et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 41:2003;431-436.
18. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:2001;851-860.
19. Berl T., Hunsicker L.G., Lewis J.B., et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 138:2003;542-549.
20. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:2001;861-869.
21. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288: 2981-2997.
22. Lindholm L.H., Ibsen H., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol . Lancet. 359:2002;1004-1010.
23. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38 . BMJ. 317:1998;703-713.
24. Grossman E., Messerli F.H. Diabetic and hypertensive heart disease. Ann Intern Med. 125:1996;304-310.
25. Bakris G.L., Williams M., Dworkin L., et al. Preserving renal function in adults with hypertension and diabetes a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group . Am J Kidney Dis. 36:2000;646-661.
26. Parving H.H., Andersen A.R., Smidt U.M., Svendsen P.A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1:1983;1175-1179.
27. Parving H.H., Smidt U.M. Hypotensive therapy reduces microvascular albumin leakage in insulin-dependent diabetic patients with nephropathy. Diabet Med. 3:1986;312-315.
28. Bakris G.L. Hypertension in diabetic patients. An overview of interventional studies to preserve renal function. Am J Hypertens. 6:(suppl):1993;140S-147S.
29. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 23:1994;145-160.
30. Viberti G., Mogensen C.E., Groop L.C., Pauls J.F. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 271:1994;275-279.
31. Fogari R., Zoppi A., Pasotti C., et al. Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function. J Hum Hypertens. 9:1995;131-135.
32. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 349:1997;1787-1792.
33. Messerli FH. ALLHAT or the soft science of the secondary endpoint. Ann Intern Med 2003;139:777-780.
34. Messerli F.H., Weber M.A. ALLHAT - all hit or all miss? Key questions still remain. Am J Cardiol. 92:2003;280-281.
35. Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis a randomized controlled trial . JAMA. 285:2001;2719-2728.
36. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO-HOPE substudy . Lancet. 355:2000;253-259.
37. Brown M.J., Castaigne A., de Leeuw P.W., et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension. 35:2000;1038-1042.